EUVIMEDEUVIMED entdecken
Crossref

A Constrained Hierarchical Bayesian Model Considering Latent Biomarker Subgroups for Time‐To‐Event Endpoints in Randomized Phase II Trials

Yifei Huang, Kentaro Takeda iD, Yongyun Zhao

Pharmaceutical Statistics · 2026-05 · 25 (3)

DOI: 10.1002/pst.70085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, online erschienen am 29.03.2026. Verfasst von Yifei Huang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Quantitative Science and Evidence Generation, Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA. Hauptthemen laut MEDLINE: Clinical Trials, Phase II as Topic, Endpoint Determination, Randomized Controlled Trials as Topic, Research Design. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In randomized Phase III oncology trials, the long‐term time‐to‐event endpoint is the most relevant outcome for participants and regulators. However, in Phase II trials, the short‐term binary outcome of tumor response is often used as a surrogate endpoint to evaluate the treatment benefit. This may lead to a high failure rate in Phase III trials, as the tumor response may not reflect the actual survival benefit. Moreover, many oncology trials collect biomarker data, especially those that may predict clinical outcomes and identify participants who are more likely to respond to the experimental treatment. Therefore, there is a growing need for a biomarker‐based design to enrich the trial by selecting participants whose biomarker levels exceed certain thresholds. This paper proposes a constrained hierarchical Bayesian model that considers latent biomarker subgroups (CHBM‐LS) for long‐term time‐to‐event endpoints in Phase II randomized trials. CHBM‐LS aggregates the biomarker populations into latent subgroups and accounts for the heterogeneity of treatment effects across biomarker levels in each model. We compare our proposed design with other approaches and show the benefits of CHBM‐LS in improving the accuracy of hazard ratio estimates and increasing the power to detect true effects while maintaining control over the Type I error rate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase II as TopicEndpoint DeterminationRandomized Controlled Trials as TopicResearch DesignModels, StatisticalBiomarkers, TumorBayes TheoremHumansBiomarkersTime FactorsTreatment Effect Heterogeneity

Stichwörter der Autor:innen

Bayesian adaptive designbiomarkerconstrained hierarchical Bayesian modelheterogeneitylatent subgroup

Substanzen

BiomarkersBiomarkers, Tumor

Autor:innen und Institutionen

  • Quantitative Science and Evidence Generation, Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA.

ORCID-Profile: Kentaro Takeda

Zitieren

APA

Huang, Y., Takeda, K., & Zhao, Y. (2026). A Constrained Hierarchical Bayesian Model Considering Latent Biomarker Subgroups for Time‐To‐Event Endpoints in Randomized Phase II Trials. Pharmaceutical Statistics, 25(3). https://doi.org/10.1002/pst.70085

Vancouver

Huang Y, Takeda K, Zhao Y. A Constrained Hierarchical Bayesian Model Considering Latent Biomarker Subgroups for Time‐To‐Event Endpoints in Randomized Phase II Trials. Pharmaceutical Statistics. 2026;25(3). doi:10.1002/pst.70085

BibTeX
@article{Huang2026,
  author = {Huang, Yifei and Takeda, Kentaro and Zhao, Yongyun},
  title = {A Constrained Hierarchical Bayesian Model Considering Latent Biomarker Subgroups for Time‐To‐Event Endpoints in Randomized Phase II Trials},
  journal = {Pharmaceutical Statistics},
  year = {2026},
  volume = {25},
  number = {3},
  doi = {10.1002/pst.70085}
}
Kostenlos starten →